

Kent Academic Repository

Full text document (pdf)

Citation for published version

Hobley, G. and Gubala, V. and Rivera-Sánchez, M.D.C. and Rivera, J.M. (2008) Synthesis of 8-heteroaryl-2'-deoxyguanosine derivatives. *Synlett* (10). pp. 1510-1514. ISSN 0936-5214.

DOI

<https://doi.org/10.1055/s-2007-1077795>

Link to record in KAR

<http://kar.kent.ac.uk/45246/>

Document Version

Author's Accepted Manuscript

Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

Enquiries

For any further enquiries regarding the licence status of this document, please contact:

researchsupport@kent.ac.uk

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>



Published in final edited form as:

Synlett. 2008 June 1; 2008(10): 1510–1514. doi:10.1055/s-2007-1077795.

Synthesis of 8-Heteroaryl-2'-deoxyguanosine Derivatives

Gerard Hoble, Vladimir Gubala¹, María del C. Rivera-Sánchez, and José M. Rivera

Department of Chemistry, College of Natural Sciences, University of Puerto Rico, Río Piedras Campus, San Juan, Puerto Rico, PR-00931

Abstract

We describe the synthesis of 8-heteroaromatic-2'-deoxyguanosine analogues using Suzuki-Miyaura or Stille conditions. Unprotected and protected 8-bromo-2'-deoxyguanosine was coupled with commercially available heteroarylboronic acids or the trialkyltin derivatives of 2-pyridylbromides either with or without microwave irradiation in good yields.

Keywords

Stille reaction; nucleosides; nucleobases; palladium; coupling

The development of efficient strategies for the synthesis of nucleoside analogues is of great importance due to their potential uses in biological applications. For example, many nucleoside analogues have found uses as antibiotics and antivirals,¹ as probes for nucleic acid structure² and as chain terminators for DNA sequencing.³ Our main interest is in guanine and its derivatives, which arises from the fact that they can self-associate to form macrocyclic, planar tetramers known as G-tetrads. These further associate through π -stacking interactions to form G-quadruplexes (GQs). These GQs can be formed from individual guanine subunits or from G-rich oligonucleotides that fold up into a variety of quadruplex structures.⁴ The cation templated self-assembly of guanosines into G-quadruplexes has been recognized since the 1960's.⁵ More recent studies of G-quadruplex formation have been in diverse areas such as cancer research and nanotechnology.^{4,6} We have demonstrated the aggregation of 8-aromatic-2'-deoxyguanosine analogues in organic solvents⁷ and have shown their selective binding of cations in some cases.⁸ We are particularly interested in the synthesis of 8-heteroaromatic-2'-deoxyguanosine (**8-(HetAr)dG**) derivatives. Heteroatoms and functional groups in the heteroaryl moieties can be used to increase the number of H-bonds. We have shown that functional groups within an 8-phenyl ring can lead to supramolecular complexes with higher stability.⁷

Since Shaughnessy's method⁹ of using the easily prepared 8-bromo-2'-deoxyguanosine (**8-BrdG**)¹⁰ and commercially available boronic acids had proven successful in the synthesis of 8-aromatic-2'-deoxyguanosine analogues (**8-ArdG**),⁷ we decided to apply it to the synthesis of **8-(HetAr)dG** targets. However, although the method is useful in the coupling of a variety of heterocycles *vide infra*, we quickly realized that we needed to use a different method to couple the 2-pyridyl moiety. Because of the expense, reported instability¹¹ and relative scarcity of commercially available, functionalized 2-pyridyl boronic acids we decided to use Stille conditions as an alternative method.¹² This is not without precedent since the Stille methodology has been used for 2-pyridylstannane couplings to various aromatic skeletons¹³

including a number of purine analogues.¹⁴ Nonetheless, to the best of our knowledge it has never been used to make **8-(HetAr)dG** derivatives. In our hands, when we tried to couple heteroaromatics to 3', 5'-isobutyric ester of 8-bromo-2'-deoxyguanosine (**3',5'-i-Bu-8-BrdG**) using heteroaromatic tin compounds, *tetrakis*triphenylphosphinepalladium in refluxing toluene,^{14f} the sole reaction product was that derived from replacement of the bromide in the substrate with a hydrogen atom. Under these conditions the reaction is extremely sluggish and on this substrate dehalogenation/ hydrogenation ensues. Recently the coupling of heteroaromatics to various guanine analogues has been reported using Stille conditions: refluxing in xylene at 150 °C, *tetrakis*triphenyl phosphinepalladium and triphenylbismuth as a co-ligand.^{14a} However this work which parallels ours does not try the coupling reaction on **3',5'-i-Bu-8-BrdG**.

Herein we report two convenient methods for the direct functionalization of the C-8 position of 2'-deoxyguanosine with heteroaromatic substituents either on **8-BrdG** using commercially available boronic acids (Suzuki-Miyaura conditions) or *via* 2-pyridylstannanes and (Stille conditions) upon **3',5'-i-Bu-8-BrdG**. The Stille reaction on this substrate is accompanied by a competitive side reaction, which by taking measures to increase the rate of Stille Coupling, can be significantly reduced. The methodology presented not only allows us to make a series of target molecules which we believe will have novel supramolecular properties but it should also be useful to others who wish to functionalise the C-8 position of guanine and its analogues.

Boronic acids (**1a**, **b** and **c**) were found to couple efficiently to **8-BrdG** using the Shaughnessy method (Scheme 1, Table 1, Entries 1, 2 and 3) to yield the **8-(HetAr)dG** derivatives **2a**, **b** and **c**.¹⁵ It was found however that the coupling reaction was very inefficient with the boronic acids **1d**, **e**, **f**. Since it has been reported that Suzuki couplings can be extremely efficient under microwave irradiation,¹⁶ we modified the methodology by treating **8-BrdG** with boronic acids (**1d**, **e**, **f**) in aqueous acetonitrile/DMF mixtures under microwave irradiation, obtaining the **8-(HetAr)dG** products (**2d**, **e**, **f**, entries 4, 5, 6).¹⁷ As shown in Scheme 1, these **8-(HetAr)dG** compounds were converted to their isobutyric esters¹⁸ (**3a-f**) for future studies of their self-assembly in organic solvents.

We next turned our attention to the synthesis of target molecule **4a** (Scheme 2). The starting secondary alcohol was protected as the benzyl ether **5a**. This was converted to the tributyltin compound **6a** in good yield. We applied a modification of the method reported by Brill and Riva-Toniolo,^{14b} where they describe the solid phase reaction of 8-bromo-2,6-diaminopurines with various organostannanes. The initial coupling under homogeneous conditions used DMF as the solvent, copper(II)oxide as additive and much less of the ligand, *bis*diphenylphosphinopropane (DPPP). We found that the reaction gave a mixture of the debrominated **7** and coupled product **4a** in a 1:1 ratio (entry 2, Table 2). Furthermore, **4a** turned out to be a 1:1 mixture of diastereoisomers as determined by proton and carbon NMR, indicating no diastereoselectivity.

However, upon changing the additive to Cu(I)oxide^{14b} and the equivalents of additive to two, we observed a significant improvement in the overall rate of the reaction and on the ratio of the two products (**7:4a**, Entry 3). Changing the ligand to triphenylarsine, which has weak donicity, led to improved yields of **4a** (Entry 4) with further improvement by changing the solvent to *N*-methylpyrrolidinone (NMP) (Entry 5). The overall optimal combination of ligand and solvent was DPPP with NMP (Entry 6). Under these conditions reducing the amount of additive (Cu(I)O), reduction in the initial amount of tin compound added or increasing the concentration of ligand (DPPP) had adverse effects on the rate of formation of the required product (data not shown). These results are in accord with those of other groups, who have sought to increase the rate of the Stille coupling reaction.^{14b-e,12b}

These results encouraged us to attempt the synthesis of more challenging **8-(2Py)dG** targets. The protected bromopyridines (**5b-d**) were converted to the tributyltin derivatives (**6b-d**). Each of these was coupled to **3',5'-i-Bu-8-BrdG** as outlined in Table 2 (Entries 7-9).¹⁹ As can be seen the coupling reaction proceeds with moderate to good yields in all cases.

We have applied a set of conditions that make the rate of the Stille coupling reaction competitive to a problematic side reaction, obtaining reasonable yields of the target molecules. Using this method or the previously reported Suzuki-Miyaura conditions and a modification of these, we are now able to synthesize a library of **8-(HetAr)dG** derivatives. We expect that these methodologies should also be useful to others who wish to attach functional groups to the C-8 position of purines.

Acknowledgments

We thank the NIH-SCoRE program for financial support, the National Science Foundation EPSCoR program for a graduate fellowship to V.G. and the NASA Space Grant program for a graduate fellowship to M.C.R.S.

References


- (1). (a) De Clercq E, Field HJ. *Br. J. Pharmacol* 2005;147:1–11. [PubMed: 16284630] (b) Simons, C. *Nucleoside Mimetics: Their Chemistry and Biological Properties*. 1 ed.. Vol. 3. Gordon & Breach; Amsterdam: 2001.
- (2). (a) Benner SA. *Acc. Chem. Res* 2004;37:784–797. [PubMed: 15491125] (b) Henry AA, Romesberg FE. *Curr. Opin. Chem. Biol* 2003;7:727–733. [PubMed: 14644182] (c) Kool ET. *Acc. Chem. Res* 2002;35:936–943. [PubMed: 12437318] (d) Kool ET, Morales JC, Guckian KM. *Angew. Chem. Int. Ed* 2000;39:990–1009.
- (3). França LTC, Carrilho E, Kist TBL. *Q. Rev. Biophys* 2002;35:169–200. [PubMed: 12197303]
- (4). Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S. *Nucleic Acids Res* 2006;34:5402–5415. [PubMed: 17012276]
- (5). Gellert M, Lipsett MN, Davies DR. *Proc. Natl. Acad. Sci. U.S.A* 1962;48:2013–2018. [PubMed: 13947099]
- (6). (a) Riou JF, Morjani H, Trentesaux C. *Ann. Pharm. Fr* 2006;64:97–105. [PubMed: 16568010] (b) Davis JT. *Angew. Chem. Int. Ed* 2004;43:668–698. (c) Pitchiaya S, Krishnan Y. *Chem. Soc. Rev* 2006;35:1111–1121. [PubMed: 17057840] (d) Feldkamp U, Niemeyer CM. *Angew. Chem. Int. Ed* 2006;45:1856–1876. (e) Beissenhirtz MK, Willner I. *Org. Biomol. Chem* 2006;4:3392–3401. [PubMed: 17036129]
- (7). Gubala V, Betancourt JE, Rivera JM. *Org. Lett* 2004;6:4735–4738. [PubMed: 15575673]
- (8). Gubala V, De Jesus D, Rivera JM. *Tetrahedron Lett* 2006;47:1413–1416.
- (9). Western EC, Daft JR, Johnson EM, Gannett PM, Shaughnessy KH. *J. Org. Chem* 2003;68:6767–6774. [PubMed: 12919046]
- (10). (a) Gillet LCJ, Schärer OD. *Organic Letters* 2002;4:4205–4208. [PubMed: 12443059] (b) Gannett PM, Sura TP. *Synth. Commun* 1993;23:1611–1615.
- (11). (a) Hodgson PB, Salingue FH. *Tetrahedron Lett* 2004;45:685–687. (b) Molander GA, Biolatto B. *J. Org. Chem* 2003;68:4302–4314. [PubMed: 12762730]
- (12). (a) Stille JK. *Angew. Chem. Int. Ed* 1986;25:508–524. (b) Farina V. *Pure & Appl. Chem* 1996;68:73–78. (c) For a recent computational analysis of the Stille Reaction, including ligand and solvent effects see: Alvarez R, Faza ON, Cardenas DJ, De Lera AR. *Adv. Synth. Catal* 2007;349:887–906. (d) Alvarez R, Faza ON, Lopez CS, De Lera AR. *Org. Lett* 2006;8:35–38. [PubMed: 16381561]
- (13). (a) Champouret YDM, Chaggar RK, Dadhiwala I, Fawcett J, Solan GA. *Tetrahedron* 2006;62:79–89. (b) Galaup C, Couchet JM, Bedel S, Tisnes P, Picard C. *J. Org. Chem* 2005;70:2274–2284. [PubMed: 15760215] (c) Lee SH, Jang BB, Kafafi ZH. *J. Am. Chem. Soc* 2005;127:9071–9078. [PubMed: 15969585] (d) Gronowitz S, Bjork P, Malm J, Hornfeldt A-B. *J. Organomet. Chem* 1993;460:127. (e) Zoppellaro G, Enkelmann V, Geies A, Baumgarten M. *Org. Lett* 2004;6:4929–

4932. [PubMed: 15606102] (f) Bour C, Suffert J. *Org. Lett* 2005;7:653–656. [PubMed: 15704917] (g) Kim DH, Ohshita J, Lee KH, Kunugi Y, Kunai A. *Organometallics* 2006;25:1511–1516.
- (14). (a) Arsenyan P, Ikaunieks M, Belyakov S. *Tetrahedron Lett* 2007;48:961–964. (b) Brill WKD, Rivatoniolo C. *Tetrahedron Lett* 2001;42:6515–6518. (c) Mamos P, Van Aerschot AA, Weyns n. J. Herdewijn PA. *Tetrahedron Lett* 1992;33:2413–2416. (d) Kaucher M,S, Davis J,T. *Tetrahedron Lett* 2006;47:6381–6384. (e) Chi T, Keane C, Eaton B,E. *Nucleosides & Nucleotides* 1995;14:1631–1638. (f) Sessler J,L, Wang B, Harriman A. *J. Am. Chem. Soc* 1995;117:704–714. (g) Ozola V, Persson T, Gronowitz S, Horfeldt A-B. *J. Heterocycl. Chem* 1995;32:863. (h) Moriarty RM, Epa WR, Awasthi AK. *Tetrahedron Lett* 1991;31:5877–5880.
- (15). Suzuki Couplings were performed according to the procedures outlined in References ⁷ and ⁹.
(2a) (391 mg, 1.14 mmol, 79 %) MP 225 °C. ¹H NMR (300 MHz; DMSO-*d*₆): δ 10.89 (br s, 1H), 8.85 (d, *J* = 2 Hz, 1H), 8.71 (dd, *J* = 5, 1 Hz, 1H), 8.09 (dt, *J* = 8, 2 Hz, 1H), 7.59 (dd, *J* = 8, 5 Hz, 1H), 6.50 (s, 2H), 6.06 (t, *J* = 7 Hz, 1H), 5.19 (d, *J* = 5 Hz, 1H), 4.96 (t, *J* = 6 Hz, 1H), 4.33 (br m, 1H), 3.80 (m, 1H), 3.64 (m, 1H), 3.53 (m, 1H), 3.17 (m, 1H), 2.08 (ddd, *J* = 13, 6, 2 Hz, 1H). ¹³C NMR (80 MHz; DMSO-*d*₆): δ 174.1, 173.6, 153.7, 151.1, 149.6, 118.8, 115.9, 83.3, 79.8, 72.1, 61.1, 31.9, 31.2, 27.1, 16.5. IR (neat)/cm⁻¹ 3206, 1677, 1631, 1560, 1244. Anal. Calcd. for: C₁₅H₁₆N₆O₄ (C 52.32, H 4.68, N 24.41); found (C 51.65, H 4.73, N 24.16). **(2b)** White solid (164 mg, 304 μmol, 88 %). MP 203 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.87 (s, 1H), 8.05 (m, 1H), 7.97 (m, 1H), 7.94 (s, 1H), 7.46 (m, 2H), 6.59 (s, 2H), 6.45 (t, *J* = 7 Hz, 1H), 5.24 (d, *J* = 5 Hz, 1H), 5.04 (t, *J* = 6 Hz, 1H), 4.46 (m, 1H), 3.88 (q, *J* = 9, 5 Hz, 1H), 3.72 (m, 1H), 3.62 (m, 1H), 3.27 (m, 1H), 2.15 (m, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 157.1, 153.7, 152.8, 141.9, 132.6, 129.3, 128.8, 128.6, 117.8, 88.5, 85.2, 71.8, 62.7, 37.1. IR (neat/cm⁻¹): 2928, 1679, 1631, 1101, 940.
(2c) Grey solid (179.4 mg, 468.0 μmol, 81 %). ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.89 (br s, 1H), 7.79 (br d, *J* = 7 Hz, 1H), 7.70 (br d, *J* = 8 Hz, 1H), 7.46 (br s, 1H), 7.43 (br t, *J* = 8 Hz, 1H), 7.36 (br t, *J* = 7 Hz, 1H), 6.57 (br s, 2H), 6.50 (t, 1H), 5.25 (br s, 1H), 4.97 (br s, 1H), 4.45 (br s, 1H), 3.85 (br s, 1H), 3.68 (m, 1H), 3.54 (m, 1H), 3.23 (quin, *J* = 7 Hz, 1H), 2.17 (br ddd, *J* = 7 Hz, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 157.1, 154.8, 154.0, 152.6, 146.5, 137.9, 128.2, 126.2, 124.2, 122.4, 118.3, 11.9, 108.5, 88.4, 84.9, 71.6, 62.5, 37.7. IR (KBr/cm⁻¹): 3144, 2949, 1678, 1566, 750.
- (16). Kappe CO. *Angew. Chem. Int. Ed* 2004;43:6250–6284.
- (17). General procedure for a microwave-assisted Suzuki Coupling using the synthesis of the compound **2d** as an example. Pd(OAc)₂ (2.10 mg, 9.30 μmol), TPPTS (13.0 mg, 23.1 μmol), Na₂CO₃ (69.5 mg, 656 μmol) and **8-BrdG** (125mg, 345 μmol) were placed in a microwave reaction vessel. To this was added 2:1:1, water: MeCN: DMF. The corresponding boronic acid (0.5 equiv of **1d**) was added and the mixture irradiated with microwaves at 100 W, 120 °C with constant cooling for 5 minutes. The addition of the boronic acid and microwave irradiation was repeated until TLC revealed that the starting material was consumed. The reaction mixture was then poured into water (25 ml) and pH was adjusted to 6-7 (0.1 M HCl). The precipitate formed was stirred at 0 °C for another 30 minutes, filtered and dried *en vacuo* to give compound **2d** as a solid (**2d**) (88.2 mg, 265 μmol, 77 %). ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.81 (s, 1H), 7.75 (d, *J* = 6 Hz, 1H), 7.50 (d, *J* = 4 Hz, 1H), 7.22 (dd, *J* = 5, 4 Hz, 1H), 6.47 (s, 2H), 6.27 (t, *J* = 8 Hz, 1H), 5.20 (d, *J* = 5 Hz, 1H), 4.96 (t, *J* = 5 Hz, 1H), 4.39 (d, *J* = 3 Hz, 1H), 3.83 (t, *J* = 3 Hz, 1H), 3.64 (m, 1H), 3.54 (m, 1H), 3.33 (m, 1H), 2.09 (m, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 156.9, 153.8, 153.0, 141.4, 140.1, 139.8, 132.9, 126.0, 125.3, 125.0, 122.7, 117.8, 88.3, 84.6, 71.2, 62.1, 31.1. IR (neat)/cm⁻¹ 1687, 1612, 1437, 999. **(2e)** (98.8 mg, 283 μmol, 82 %). ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.11 (s, 1H), 7.92 (s, 1H), 6.96 (d, *J* = 4 Hz, 1H), 6.70 (dd, *J* = 3, 2 Hz, 1H), 6.56 (s, 2H), 6.38 (t, *J* = 7 Hz, 1H), 5.21 (d, *J* = 4 Hz, 1H), 5.10 (br s, 1H), 4.40 (br s, 1H), 3.81 (t, *J* = 3 Hz, 1H), 3.64 (m, 1H), 3.51 (m, 1H), 3.18 (m, 1H), 2.10 (m, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 152.4, 145.0, 144.9, 138.2, 120.4, 118.2, 116.8, 112.6, 111.5, 88.6, 85.3, 71.9, 62.9, 37.8. IR (neat)/cm⁻¹ 1688, 1619, 1527, 1446, 1379, 951. **(2f)** Grey solid (45 mg, 135 μmol, 94 %). ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.76 (br s, 1H), 8.17 (s, 1H), 7.86 (t, *J* = 1 Hz, 1H), 6.87 (br d, *J* = 1 Hz, 1H), 6.43 (br s, 2H), 6.17 (t, 1H), 5.22 (d, 1H), 5.00 (t, 1H), 4.40 (br dt, *J* = 3 Hz, 1H), 3.81 (m, 1H), 3.64 (m, 1H), 3.55 (m, 1H), 3.22 (q, *J* = 7 Hz, 1H), 2.09 (ddd, *J* = 7, 3 Hz, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 157.3, 153.6, 152.6, 144.6, 143.3, 140.9, 117.6, 117.0, 111.6, 88.4, 84.7, 71.4, 62.5, 37.2. IR (KBr/cm⁻¹): 3341, 3143, 2919, 1678, 1568, 877.
- (18). Esterifications were performed according to the procedures outlined in Reference ⁷. **(3a)** (63.0 mg, 129 μmol, 89 %). MP 126 °C. ¹H NMR (500 MHz; DMSO-*d*₆): δ 11.0 (br s, 1H), 8.88 (d, *J* = 2 Hz,


1H.), 8.74 (dd, $J = 5, 1$ Hz), 8.10 (d, $J = 8$ Hz, 1H), 7.68 (dd, $J = 5, 8$ Hz), 6.61 (s, 2H), 6.13 (t, $J = 7$ Hz, 1H), 5.50 (q, $J = 3$ Hz, 1H), 4.45 (dd, $J = 11, 5$ Hz, 1H), 4.30 (dd, $J = 11, 7$ Hz, 1H), 4.20 (m, 1H), 3.57 (q, $J = 7$ Hz, 1H), 2.57 (m, 2H), 2.44 (q, $J = 5$ Hz, 1H), 1.12 (d, $J = 2$ Hz, 1H), 1.10 (s, 6H), 1.08 (s, 3H). ^{13}C NMR (125 MHz; DMSO- d_6): δ 176.0, 175.7, 156.7, 153.3, 152.1, 150.2, 139.3, 144.2, 136.5, 126.3, 123.6, 117.4, 84.72, 81.8, 74.7, 63.5, 34.0, 33.1, 33.0, 18.71, 18.68, 18.60, 18.59. IR (neat)/ cm^{-1} 1727, 1689, 1627, 1150. Anal. Calcd. for: $\text{C}_{23}\text{H}_{28}\text{N}_6\text{O}_6$ (C 57.02, H 5.82, N 17.35); found (C 54.86, H 5.99, N 15.51). (3b) (128 mg, 237 μmol , 91 %). MP 201 °C. ^1H NMR (500 MHz, DMSO- d_6): δ 10.83 (s, 1H), 8.01 (m, 1H), 7.93 (m, 2H), 7.42 (m, 2H), 6.54 (s, 2H), 6.41 (t, $J = 7$ Hz, 1H), 5.00 (t, $J = 6$ Hz, 1H), 4.42 (m, 1H), 3.68 (m, 1H), 3.57 (m, 1H), 3.23 (m, 1H), 2.53 (m, 2H), 2.09 (m, 1H), 1.10 (m, 6H), 1.05 (m, 6H). ^{13}C NMR (125 MHz, DMSO- d_6): δ 206.9, 175.8, 175.6, 156.9, 153.7, 153.0, 141.4, 140.1, 139.8, 132.9, 126.0, 125.3, 125.0, 122.7, 117.8, 88.3, 84.6, 71.2, 62.1, 37.2, 31.1, 18.5, 18.4. IR (neat)/ cm^{-1} 1734, 1683, 1635, 1597, 1190, 1156. Anal. Calcd. for: $\text{C}_{26}\text{H}_{29}\text{N}_5\text{O}_6\text{S}$ (C 57.87, H 5.42, N 12.96); found (C 58.03, H 5.67, N 12.59). (3c) Yellow solid (133.8 mg, 256 μmol , 65 %). ^1H NMR (500 MHz, DMSO- d_6): δ 11.04 (br s, 1H), 7.78 (d, $J = 7$ Hz, 1H), 7.69 (d, $J = 8$ Hz, 1H), 7.44 (br s, 1H), 7.43 (br t, $J = 8$ Hz, 1H), 7.36 (t, $J = 7$ Hz, 1H), 6.66 (br s, 2H), 6.65 (m, 1H), 5.56 (br d, 1H), 4.45 (br d, 1H), 4.28 (br d, 1H), 4.24 (m, 1H), 3.58 (br quin, 1H), 2.61 (br quin, $J = 7$ Hz, 1H), 2.50 (m, 1H), 2.47 (m, 1H), 1.14 (d, $J = 7$ Hz, 1H), 1.05 (d, 1H). ^{13}C NMR (125 MHz, DMSO- d_6): δ 176.8, 176.5, 157.8, 155.0, 154.5, 152.8, 146.6, 138.1, 128.3, 126.42, 124.41, 122.6, 118.5, 112.0, 108.5, 85.3, 82.5, 75.3, 64.3, 35.2, 33.9, 33.8, 19.3, 19.3. IR (KBr/ cm^{-1}): 3308, 3138, 2973, 2935, 2877, 1737, 1687, 1570, 1258, 751. (3d) (113 mg, 231 μmol , 89 %). MP 134 °C. ^1H NMR (500 MHz, DMSO- d_6): δ 10.85 (s, 1H), 7.76 (d, $J = 5$ Hz, 1H), 7.48 (d, $J = 5$ Hz, 1H), 7.10 (dd, $J = 5, 4$ Hz), 6.53 (s, 2H), 6.32 (t, $J = 7$ Hz, 1H), 5.50 (m, 1H), 4.32 (m, 1H), 4.30 (m, 1H), 4.20 (m, 1H), 3.64 (m, 1H), 2.57 (m, 2H), 2.43 (m, 1H), 1.11 (m, 6H), 1.05 (m, 6H). ^{13}C NMR (125 MHz, DMSO- d_6): δ 176.6, 176.4, 157.1, 153.8, 152.7, 141.9, 132.5, 129.4, 128.7, 128.5, 117.7, 85.3, 82.5, 75.4, 64.1, 34.5, 33.7, 19.3. IR (neat)/ cm^{-1} 1733, 1672, 1593, 1152. Anal. Calcd. for: $\text{C}_{22}\text{H}_{27}\text{N}_5\text{O}_6\text{S}$ (C 53.98, H 5.56, N 14.31); found (C 53.84, H 6.01, N 14.27). (3e) (111 mg, 234 μmol , 90 %). MP 167 °C. ^1H NMR (500 MHz, DMSO- d_6): δ 10.88 (s, 1H), 7.90 (d, $J = 5$ Hz, 1H), 6.96 (d, $J = 5$ Hz, 1H), 6.69 (dd, $J = 5, 4$ Hz, 1H), 6.54 (s, 2H), 6.44 (t, $J = 7$ Hz, 1H), 5.46 (m, 1H), 4.40 (m, 1H), 4.22 (m, 1H), 4.16 (m, 1H), 3.50 (m, 1H), 2.57 (m, 2H), 2.41 (m, 1H), 1.12 (m, 6H), 1.03 (m, 6H). ^{13}C NMR (125 MHz, DMSO- d_6): δ 176.6, 176.3, 157.1, 153.9, 152.3, 145.1, 144.7, 138.4, 117.9, 112.9, 112.5, 85.1, 82.3, 75.3, 64.3, 35.0, 33.7, 19.3. IR (neat/ cm^{-1}): 1732, 1681, 1153, 1077, 764. Anal. Calcd. for: $\text{C}_{22}\text{H}_{27}\text{N}_5\text{O}_7$ (C 55.81, H 5.75, N 14.79); found (C 55.44, H 6.02, N 14.67). (3f) Yellow solid (228 mg, 481 μmol , 80 %). ^1H NMR (500 MHz, DMSO- d_6): δ 10.83 (br s, 1H), 8.14 (s, 1H), 7.87 (t, $J = 1$ Hz, 1H), 6.88 (d, $J = 1$ Hz, 1H), 6.50 (br s, 2H), 6.22 (t, 1H), 5.49 (quin, $J = 7, 4$ Hz, 1H), 4.40 (m, 1H), 4.24 (m, 1H), 4.19 (br ddd, $J = 7$ Hz, 1H), 3.61 (quin, $J = 7$ Hz, 1H), 2.59 (quin, $J = 7$ Hz, 1H), 2.52 (br quin, $J = 7$ Hz, 1H), 2.43 (ddd, $J = 7, 4$ Hz, 1H), 1.12 (dd, $J = 7$ Hz, 1H), 1.05 (dd, $J = 7$ Hz, 1H). ^{13}C NMR (125 MHz, DMSO- d_6): δ 176.4, 176.2, 157.0, 153.5, 152.3, 144.6, 142.7, 140.8, 117.5, 116.7, 111.3, 84.8, 82.1, 75.1, 64.0, 34.4, 33.6, 33.6, 19.2, 19.2, 19.1, 19.1. IR (KBr/ cm^{-1}): 1738, 1687, 1596, 1254, 875.

- (19). General procedure for a Stille Coupling using the synthesis of compound **4a** as an example. **3',5'-i-Bu-8-BrdG** (50.0 mg, 103 μmol), DPPP (6.35 mg, 15.4 μmol), Pd(OAc) $_2$ (3.45 mg, 15.4 μmol), Cu $_2$ O (29.5 mg, 206 μmol) and NMP (490 μL) were mixed. After this, compound **6a** (115 mg, 206 μmol) was added to the mixture. The mixture was heated to 115 °C for 1 hour after which HPLC analysis of the crude reaction mixture showed that the starting material was consumed. Therefore, the mixture was filtered through celite and the solvents removed under reduced pressure. The product was isolated by column chromatography (50 % EtOAc in Et $_2$ O) yielding **4a** as a white solid (47.0 mg, 75.9 μmol , 74 %). MP 169 °C. ^1H NMR (500 MHz; DMSO- d_6): δ 10.89 (s, 1H), 8.02 (m, 2H), 7.58 (m, 2H), 7.36 (m, 4H), 7.30 (m, 1H), 6.54 (s, 2H), 5.46 (m, 1H), 4.67 (q, $J = 7$ Hz, 1H), 4.53 (s, 1H), 4.51 (s, 1H), 4.47 (m, 1H), 4.31 (m, 1H), 4.06 (m, 1H), 3.59 (m, 1H), 2.50 (m, 2H), 2.34 (m, 1H), 1.53 and 1.51 (d, $J = 7$ Hz, 3H), 1.15-1.06 (m, 12H). ^{13}C NMR (125 MHz; DMSO- d_6): δ 176.0, 175.5, 161.27, 156.6, 153.2, 152.7, 149.0, 143.7, 143.6, 138.4, 138.1, 128.19, 128.17, 127.39, 127.36, 122.3, 120.1, 117.3, 85.4, 81.4, 77.3, 74.9, 70.1, 63.6, 33.9, 33.1, 21.4, 21.3, 18.7, 18.6, 18.5. IR (neat)/ cm^{-1} 1732, 1690, 1631, 1587, 1156. Anal. Calcd. for: $\text{C}_{32}\text{H}_{38}\text{N}_6\text{O}_7$ (C 62.12, H 6.19, N 13.58); found (C 60.88, H 6.15, N 12.98). (4b) White solid (253 mg, 398 μmol , 80 %). MP 209 °C. ^1H NMR (500 MHz; DMSO- d_6): δ 10.89 (s, 1H), 8.01 (m, 2H), 7.55 (m, 2H), 7.28 (d, $J = 8$ Hz, 2H), 6.91 (d, $J = 8$ Hz, 2H), 6.54 (s, 2H), 5.45 (m, 1H), 4.64 (m,

1H), 4.48 (m, 1H), 4.45 (d, $J=14$ Hz, 1H), 4.43 (d, $J=14$ Hz, 1H), 4.07 (m, 1H), 3.58 (m, 1H), 2.35 (m, 1H), 1.49 (t, $J=6$ Hz, 3H), 1.09 (d, $J=7$ Hz, 6H), 1.07 (d, $J=7$ Hz, 6H). ^{13}C NMR (125 MHz; DMSO- d_6); δ 176.0, 175.6, 161.4, 158.7, 156.6, 153.2, 149.0, 143.6, 138.2, 130.3, 129.09, 129.07, 122.3, 120.1, 117.4, 113.59, 113.57, 85.4, 81.4, 76.94, 76.90, 74.9, 69.7, 63.7, 55.0, 48.4, 33.9, 33.1, 30.1, 29.0, 21.4, 21.3, 18.6, 18.53, 18.49, 17.2. IR (neat)/ cm^{-1} 1724, 1681, 1635, 1566, 1153, 817. Anal. Calcd. for: $\text{C}_{33}\text{H}_{40}\text{N}_6\text{O}_8$ (C 61.10, H 6.22, N 12.96); found (C 60.61, H 6.20, N 12.88). **(4c)** White solid (192 mg, 302 μmol , 60 %). MP 182 $^\circ\text{C}$. ^1H NMR (500 MHz; DMSO- d_6); δ 10.91 (s, 1H), 8.00 (m, 2H), 7.54 (m, 2H), 7.33 (d, $J=8$ Hz, 2H), 6.93 (d, $J=8$ Hz, 2H), 6.57 (s, 2H), 5.50 (m, 1H), 4.65 (s, 2H), 4.58 (s, 2H), 4.88 (dd, $J=12, 6$ Hz, 1H), 4.29 (dd, $J=12, 7$ Hz, 1H), 4.09 (m, 1H), 3.76 (s, 3H), 3.50 (m, 1H), 2.52 (m, 2H), 2.35 (m, 1H), 1.10 (d, $J=7$ Hz, 6H) 1.07 (d, $J=7$ Hz, 6H). ^{13}C NMR (125 MHz; DMSO- d_6); δ 176.0, 175.5, 158.8, 157.3, 156.7, 153.3, 152.7, 149.1, 143.5, 138.1, 130.0, 129.2, 122.4, 121.1, 117.3, 113.7, 85.1, 81.4, 74.8, 71.9, 71.6, 63.8, 55.0, 34.4, 33.12, 33.09, 18.7, 18.6. IR (neat)/ cm^{-1} 1734, 1691, 1629, 1588, 1571, 1249. Anal. Calcd. for: $\text{C}_{32}\text{H}_{38}\text{N}_6\text{O}_8$ (C 60.56, H 6.03, N 13.24); found (C 60.65, H 6.00, N 13.12). **(4d)** White solid (187 mg, 305 μmol , 61 %). MP 193 $^\circ\text{C}$. ^1H NMR (500 MHz; DMSO- d_6); δ 10.88 (s, 1H), 7.99 (m, 2H), 7.56 (t, $J=7$ Hz, 1H), 7.47 (d, $J=7$ Hz, 1H), 6.55 (br s, 2H), 5.50 (m, 1H), 4.59 (s, 1H), 4.47 (dd, $J=12, 6$ Hz, 1H), 4.26 (dd, $J=12, 7$ Hz, 1H), 4.09 (m, 1H), 3.66 (t, $J=8$ Hz, 2H), 3.49 (m, 1H), 2.60 (m, 1H), 2.52 (m, 1H), 2.37 (m, 1H), 1.14 (dd, $J=7, 3$ Hz, 6H), 1.06 (d, $J=7$ Hz, 6H), 0.99 (t, $J=8$ Hz, 2H), 0.03 (s, 9H). ^{13}C NMR (125 MHz; DMSO- d_6); δ 175.9, 175.5, 157.6, 156.6, 153.3, 152.7, 148.9, 143.5, 138.0, 122.2, 120.6, 117.3, 85.1, 81.4, 74.8, 72.4, 67.6, 63.8, 34.5, 33.2, 33.1, 18.69, 18.65, 17.7, -1.30. IR (neat)/ cm^{-1} 1731, 1671, 1564, 1460, 1189. Anal. Calcd. for: $\text{C}_{29}\text{H}_{42}\text{N}_6\text{O}_7\text{Si}$ (C 56.66, H 6.89, N 13.67); found (C 56.59, H 6.89, N 12.85).



Scheme 1.
 Synthesis of **8-(HetAr)*d*G** derivatives.



Scheme 2.
 Synthesis of 3',5'-*i*-Bu-8-(2Py)*dG* analogues.

Table 1Results for the synthesis of **8-(HetAr)dG** derivatives from commercially available boronic acids and **8-BrdG**

Entry	Boronic acid	Product/yield ^{a)}	Ester/yield ^{a)}
1	1a ⁱ	2a / 79%	3a / 89 %
2	1b ⁱ	2b / 88 %	3b / 91 %
3	1c ⁱ	2c / 81 %	3c / 65 %
4	1d ⁱⁱ	2d / 77 %	3d / 89 %
5	1e ⁱⁱ	2e / 82 %	3e / 90 %
6	1f ⁱⁱ	2f / 94 %	3f / 80 %

Conditions (i) and (ii) see Scheme 1

^{a)} isolated yield.

Table 2Coupling of 2-pyridyl stannanes to **3',5'-i-Bu-8-BrdG** under various conditions

Entry ^(e)	Tin compound ^(a)	Additive/ Equiv	Reaction time (h)	Ligand/ equiv ^(b)
1	6a	None	3.5	DPPP/ 0.66
2	6a	CuO/ 1	14	DPPP/ 0.66
3	6a	Cu ₂ O/ 2	1	DPPP/ 1
4	6a	Cu ₂ O/ 2	1	AsPh ₃ / 2
5	6a	Cu ₂ O/ 2	1	AsPh ₃ / 2
6	6a	Cu ₂ O/ 2	1	DPPP/ 1
7	6b	Cu ₂ O/ 2	1	DPPP/ 1
8	6c	Cu ₂ O/ 2	1	DPPP/ 1
9	6d	Cu ₂ O/ 2	1	DPPP/ 1

Entry ^(e)	Solvent	% Conv. ^(c)	Ratio 7:4a	Yield
1	DMF	33	1.2: 1 ^(c)	Nd
2	DMF	Nd	1: 1 ^(d)	4a / 39 % ^(d)
3	DMF	>98	1: 6.3 ^(c)	4a / 70 % ^(c)
4	DMF	>98	1: 6.0 ^(c)	4a / 57 % ^(c)
5	NMP	>98	1: 6.2 ^(c)	4a / 59 % ^(c)
6	NMP	>98	1: 7.7 ^(c)	4a / 74 % ^(d)
7	NMP	Nd	Na	4b / 80 % ^(d)
8	NMP	Nd	Na	4c / 60 % ^(d)
9	NMP	Nd	Na	4d / 61 % ^(d)

^(a) 2.0 equivalents used in all cases^(b) with respect to the palladium^(c) Calculated by HPLC analysis of the crude reaction mixtures; (Nd) not done; (Na) not applicable^(d) isolated yield^(e) other conditions: **3',5'-i-Bu-8-BrdG** (50 mg in 490 μ L of solvent), 15 mol % Pd(OAc)₂, 115 °C.